Inclusion Criteria:

1. Age 18 years or over

2. Histologically confirmed marginal zone B-cell lymphoma of MALT-type

3. Lymphoma localised to the ocular adnexae (conjunctiva, lacrimal gland, orbit soft
tissue, clinical stage IEA) following a CT scan of neck, thorax, abdomen and pelvis,
bone marrow aspirate/trephine, full blood count and biochemical profile

4. No previous treatment, excepting RT for localised lymphoma of the contralateral eye

5. At least one measurable lesion

6. No systemic antibiotic therapy in the last three months

7. No other malignancy in the previous 5 years apart from appropriately treated basal
cell carcinoma of the skin or carcinoma in situ of the cervix

8. In women with reproductive potential a willingness to use contraception from entry
into the study for a period of 3 months

9. Written informed consent

Exclusion Criteria:

1. Pregnant or lactating women

2. Known allergy to tetracycline

3. Patients unwilling to comply with the requirements of follow-up as defined by this
protocol

4. Myasthenia gravis (tetracycline can exacerbate muscle weakness)

5. Systemic lupus erythematous (tetracycline can exacerbate the condition)

6. Patients with large or rapidly enlarging tumours requiring immediate radiotherapy